AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30482701 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study 28012280 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (60 g/day)
Number of subjects: 63
Study 28012280 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (60 g/day)
Number of subjects: 63
Study 28012280 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fat high in MC-SFA (63 g/day)
Number of subjects: 63
Study 28012280 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fat low in MC-SFA (63 g/day)
Number of subjects: 63
Study 26296511 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (up titrated from 2 to 8 mg/d, or highest tolerated dose)
Number of subjects: 164
Study 26296511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 23206874 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hand action effects
Number of subjects: 0
Study 23206874 — intervention group
Group type: COMPARATOR
Intervention: Right-hand action effects
Number of subjects: 0
Study 23206874 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative learning for left-hand effects
Number of subjects: 0
Study 23206874 — intervention group
Group type: COMPARATOR
Intervention: Associative learning for right-hand effects
Number of subjects: 0
Study 21251654 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary counseling and rapid testing (VCT) during labor
Number of subjects: 343
Study 21251654 — intervention group
Group type: COMPARATOR
Intervention: Voluntary counseling and rapid testing (VCT) after delivery
Number of subjects: 343
Study 18433534 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) during CPB
Number of subjects: 261
Study 18433534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MUF)
Number of subjects: 261
Study 17067973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 29
Study 14661567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg bolus injection 3 minutes before propofol injection, followed by continuous infusion at 6 mg.h‐1)
Number of subjects: 120
Study 14661567 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (Group C)
Number of subjects: 120
Study 10617942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek cell phospholipids from infants fed formulas with varying DHA and arachidonic acid intakes
Number of subjects: 31
Study 8720807 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide suppositories
Number of subjects: 8
Study 8720807 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide sodium suppositories
Number of subjects: 8
Study 2179481 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (THP at 6 hours, then cisplatin from 16 to 20 hours)
Number of subjects: 31
Study 2179481 — intervention group
Group type: COMPARATOR
Intervention: Schedule B (THP at 18 hours, then cisplatin from 4 to 8 hours)
Number of subjects: 31
Study 2179481 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A
Number of subjects: 31
Study 2179481 — intervention group
Group type: COMPARATOR
Intervention: Schedule B
Number of subjects: 31
Study 2179481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 31
Study 7427858 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR), 60 mg/M2 I.V. q three weeks
Number of subjects: 72
Study 7427858 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 40 mg/M2 I.V. q one week
Number of subjects: 72
Study 7427858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), 500 mg/m2 I.V. x 5 days q five weeks
Number of subjects: 72
Study 31256606 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention for family members in ICUs
Number of subjects: 380
Study 31256606 — intervention group
Group type: EXPERIMENTAL
Intervention: Better family relationship at baseline
Number of subjects: 380
Study 27974712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ledipasvir (LDV) therapy
Number of subjects: 147
Study 26466473 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nail (Group A)
Number of subjects: 72
Study 26466473 — intervention group
Group type: COMPARATOR
Intervention: Locking compression plate (Group B)
Number of subjects: 72
Study 23438509 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0
Study 23438509 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22123897 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 224
Study 22123897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 22123897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum positivity
Number of subjects: 224
Study 20337221 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 94
Study 17030169 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-950 450 mg every 8 hours
Number of subjects: 34
Study 17030169 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-950 750 mg every 8 hours
Number of subjects: 34
Study 17030169 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-950 1250 mg every 12 hours
Number of subjects: 34
Study 17030169 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-950 (all doses)
Number of subjects: 34
Study 17030169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12771500 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Copper Cement (BCC)
Number of subjects: 45
Study 12771500 — intervention group
Group type: COMPARATOR
Intervention: Glass Ionomer Cement (GIC)
Number of subjects: 45
Study 10672977 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 100 mg
Number of subjects: 12
Study 10672977 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 200 mg
Number of subjects: 12
Study 10672977 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 9146587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Tice strain BCG
Number of subjects: 30
Study 9146587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7962893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy (BT)
Number of subjects: 36
Study 7962893 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (GT)
Number of subjects: 36
Study 7962893 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 36
Study 2888813 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 12
Study 2888813 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (1 mg l-1)
Number of subjects: 12
Study 2888813 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (2 mg l-1)
Number of subjects: 12
Study 2888813 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 12
Study 2888813 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 12
Study 29188336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ACLR (within 8 days)
Number of subjects: 70
Study 29188336 — intervention group
Group type: COMPARATOR
Intervention: Delayed ACLR (6-10 weeks)
Number of subjects: 70
Study 28090594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 24943105 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4000 (8 g per day)
Number of subjects: 88
Study 24943105 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (3.3 g per day)
Number of subjects: 88
Study 24943105 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4000
Number of subjects: 88
Study 24943105 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 88
Study 24943105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 21741230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges
Number of subjects: 200
Study 21741230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 20828645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg bid
Number of subjects: 191
Study 20828645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg bid
Number of subjects: 191
Study 20828645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1500 mg bid
Number of subjects: 191
Study 20828645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 19075481 — intervention group
Group type: EXPERIMENTAL
Intervention: First day discharge (group B, n = 37)
Number of subjects: 56
Study 19075481 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital stay (group A, n = 19)
Number of subjects: 56
Study 19075481 — intervention group
Group type: COMPARATOR
Intervention: Ejection fraction after 30 days (group A)
Number of subjects: 56
Study 19075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction after 30 days (group B)
Number of subjects: 56
Study 19075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 56
Study 15729252 — intervention group
Group type: EXPERIMENTAL
Intervention: Video headset
Number of subjects: 96
Study 15729252 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitor
Number of subjects: 96
Study 12847356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway of controlled rehabilitation with early ambulation and diet
Number of subjects: 64
Study 12847356 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative care
Number of subjects: 64
Study 10389680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (840 mg, range: 80-1920 mg)
Number of subjects: 25
Study 10389680 — intervention group
Group type: COMPARATOR
Intervention: Morphine (238 mg, range: 20-1125 mg)
Number of subjects: 25
Study 8657100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (BL)
Number of subjects: 8
Study 8657100 — intervention group
Group type: COMPARATOR
Intervention: Dim Light (DL)
Number of subjects: 8
Study 1357451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 2.4 g daily for 24 months
Number of subjects: 350
Study 3890986 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSB (prothrombin complex preparation)
Number of subjects: 268
Study 3890986 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PPSB)
Number of subjects: 268
Study 30348142 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education via a smartphone app (unidirectional text messages, evidence and psychological theory based, regarding dietary habits, physical activity, hypoglycaemia, and glucose variability) for 6 or 9 months, frequency chosen by patients (2-6 times per week).
Number of subjects: 228
Study 30348142 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group).
Number of subjects: 228
Study 30348142 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education via a smartphone app.
Number of subjects: 228
Study 26394360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron treatment (80 mg/day for 4 weeks)
Number of subjects: 145
Study 26394360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 24868583 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% topical unoprostone twice daily in a randomly selected eye
Number of subjects: 40
Study 24868583 — intervention group
Group type: COMPARATOR
Intervention: Control RP patients
Number of subjects: 40
Study 21993491 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1021
Study 21993491 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1021
Study 20178625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium vegetable juice (8 or 16 fluid ounces daily)
Number of subjects: 81
Study 20178625 — intervention group
Group type: COMPARATOR
Intervention: Diet counseling only (control group)
Number of subjects: 81
Study 18430966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate with protein (CHO + PRO)
Number of subjects: 10
Study 18430966 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 10
Study 16223056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 0
Study 16223056 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Management (MM)
Number of subjects: 0
Study 16223056 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 90 AIR/ED
Number of subjects: 0
Study 12586793 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m(2))
Number of subjects: 739
Study 12586793 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m(2)/24 h)
Number of subjects: 739
Study 12586793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and paclitaxel (AT, 50 mg/m(2) and 150 mg/m(2)/24 h, plus granulocyte colony‐stimulating factor 5 mg/kg)
Number of subjects: 739
Study 12586793 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 739
Study 12586793 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 739
Study 12586793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and paclitaxel (AT)
Number of subjects: 739
Study 12586793 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin to Paclitaxel crossover
Number of subjects: 739
Study 12586793 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel to Doxorubicin crossover
Number of subjects: 739
Study 10028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline Follow‐Back (TLFB)
Number of subjects: 65
Study 10028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly calendar reports
Number of subjects: 65
Study 10028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐report measures
Number of subjects: 65
Study 10028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐report measures over time
Number of subjects: 65
Study 8694157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg added to prilocaine in a standard Bier's block (group 2)
Number of subjects: 45
Study 8694157 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 45
Study 8694157 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Bier's block with tenoxicam given intravenously into the contralateral arm (group 3)
Number of subjects: 45
Study 1997063 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia with local anaesthetics for 3 days
Number of subjects: 48
Study 1997063 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 48
Study 7061773 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) received a mean cumulative dose of 3440 microgram cat allergen 1 (cat 1) and 10,660 microgram cat albumin (alb).
Number of subjects: 16
Study 7061773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose group (IDG) received 70 microgram cat 1 and 217 microgram alb.
Number of subjects: 16
Study 7061773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) received 0.930 microgram cat 1 and 2.86 microgram alb.
Number of subjects: 16
Study 31454771 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 25
Study 31454771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet group (MDG)
Number of subjects: 63
Study 29947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle group (MLG)
Number of subjects: 63
Study 29947322 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63
Study 27247174 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goals‐Collaborative Care (LG‐CC)
Number of subjects: 219
Study 24664108 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (intelligence test HAWIK‐IV)
Number of subjects: 62
Study 24664108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (running at 65‐75% of maximum heart rate for 15 minutes)
Number of subjects: 62
Study 24664108 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular school lesson)
Number of subjects: 62
Study 22281403 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 236
Study 22281403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 22281403 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy in patients with VRS
Number of subjects: 236
Study 22281403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chest physiotherapy) in patients with VRS
Number of subjects: 236
Study 20932401 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drinks (various types)
Number of subjects: 9
Study 18803940 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg/d
Number of subjects: 41
Study 18803940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 18803940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 41
Study 15860766 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12165641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil-based chemotherapy
Number of subjects: 3380
Study 10434212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative analgesia
Number of subjects: 471
Study 10434212 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional analgesia (subset of 185 patients with genitourinary procedures)
Number of subjects: 471
Study 10434212 — intervention group
Group type: COMPARATOR
Intervention: Poor pain relief
Number of subjects: 471
Study 7887699 — intervention group
Group type: EXPERIMENTAL
Intervention: Kety-Schmidt technique
Number of subjects: 20
Study 7887699 — intervention group
Group type: COMPARATOR
Intervention: Xenon-133 clearance
Number of subjects: 20
Study 2624617 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potassium diet (10 mmol per day)
Number of subjects: 10
Study 2624617 — intervention group
Group type: COMPARATOR
Intervention: Normal-potassium diet (90 mmol per day)
Number of subjects: 10
Study 2624617 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion in potassium-depleted subjects
Number of subjects: 10
Study 31559589 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (300,000 IU for deficiency, 150,000 IU for insufficiency) administered orally 48 hours before CABG surgery
Number of subjects: 116
Study 31559589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 116
Study 31559589 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 116
Study 29779316 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial kidney seeper group (inserted by a ureteral catheter)
Number of subjects: 287
Study 29779316 — intervention group
Group type: COMPARATOR
Intervention: Non-artificial kidney seeper group (underwent PCNL directly)
Number of subjects: 287
Study 27935423 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral balance training (dominant leg) over 4 weeks (4×/week)
Number of subjects: 51
Study 27935423 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral balance training (dominant leg)
Number of subjects: 51
Study 27935423 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study 25172701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice with 10% refined olive oil (750g/70kg BW)
Number of subjects: 11
Study 25172701 — intervention group
Group type: COMPARATOR
Intervention: Tomato juice without oil (750g/70kg BW)
Number of subjects: 11
Study 23772760 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the Short Inventory of Problems (SIP-RS)
Number of subjects: 405
Study 20885426 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPen rebound tonometer
Number of subjects: 198
Study 20885426 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 198
Study 20885426 — intervention group
Group type: COMPARATOR
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 198
Study 18781066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% starch gel-like solution
Number of subjects: 11
Study 18781066 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose solution
Number of subjects: 11
Study 18781066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% starch and 10% sucrose solution
Number of subjects: 11
Study 18781066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% starch solution followed by 10% sucrose solution
Number of subjects: 11
Study 18781066 — intervention group
Group type: COMPARATOR
Intervention: Starch (2%)
Number of subjects: 11
Study 18781066 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (10%)
Number of subjects: 11
Study 18781066 — intervention group
Group type: COMPARATOR
Intervention: Starch + Sucrose
Number of subjects: 11
Study 16781376 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 458
Study 16781376 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study 14981969 — intervention group
Group type: EXPERIMENTAL
Intervention: Levovist power Doppler ultrasound (Levovist US)
Number of subjects: 46
Study 14981969 — intervention group
Group type: COMPARATOR
Intervention: Spiral computed tomography (spiral CT)
Number of subjects: 46
Study 11069341 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tunnelling with a loop for epidural catheter fixation (n = 34)
Number of subjects: 68
Study 11069341 — intervention group
Group type: COMPARATOR
Intervention: Simple loop of epidural catheter left over the skin (Control group, n = 34)
Number of subjects: 68
Study 8709402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 8709402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegorgotein 10 000 U/kg
Number of subjects: 463
Study 8709402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegorgotein 20 000 U/kg
Number of subjects: 463